The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB). The Committee first heard from the Minister of Health, the Honourable Jean-Yves Duclos. The Minister’s appearance was followed by witnesses from the Department of Health and the Department of Justice, as well as Mélanie Bourassa Forcier, Professor at the University of Sherbrooke and the former Acting Chair of the PMPRB.
The Committee will reconvene on May 2, 2023, to hear from Matthew Herder, Associate Professor at Dalhousie University and former board member of the PMPRB, as well as the current Executive Director of the PMPRB, Douglas Clark.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency releases updated Procedures for Reimbursement Reviews & new data on Health Technology Assessment timelines
On April 30, 2026, Canada’s Drug Agency (CDA) published updated Procedures for Reimbursement Reviews, following completion of a public consultation earlier this year. The updated procedures will be ef...Read More -
PMPRB releases May NEWSLetter and Meds Pipeline Monitor
On May 12, 2026, the Patented Medicine Prices Review Board (PMPRB) released its May NEWSLetter. The NEWSletter provides updates on the implementation of the new Guidelines for PMPRB Staff, the consult...Read More -
2026 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2026, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top storiesRead More
